RU2015111612A - Pharmaceutical composition based on 3- (3,5-Dimethylpyrazol-1-yl) imidazo [1,2-b] [1,2,4,5] tetrazine as an antitumor agent - Google Patents

Pharmaceutical composition based on 3- (3,5-Dimethylpyrazol-1-yl) imidazo [1,2-b] [1,2,4,5] tetrazine as an antitumor agent Download PDF

Info

Publication number
RU2015111612A
RU2015111612A RU2015111612A RU2015111612A RU2015111612A RU 2015111612 A RU2015111612 A RU 2015111612A RU 2015111612 A RU2015111612 A RU 2015111612A RU 2015111612 A RU2015111612 A RU 2015111612A RU 2015111612 A RU2015111612 A RU 2015111612A
Authority
RU
Russia
Prior art keywords
dimethylpyrazol
tetrazine
imidazo
pharmaceutical composition
composition based
Prior art date
Application number
RU2015111612A
Other languages
Russian (ru)
Other versions
RU2614234C2 (en
Inventor
Валерий Николаевич Даниленко
Валерий Николаевич Чарушин
Геннадий Леонидович Русинов
Алина Александровна Маркова
Рашида Иршотовна Ишметова
Серикбай Каримович Абилев
Нина Константиновна Игнатенко
Светлана Геннадьевна Толщина
Анатолий Васильевич Ратькин
Александр Альбертович Штиль
Original Assignee
Федеральное государственное бюджетное учреждение науки Институт общей генетики им. Н.И. Вавилова Российской академии наук (ИОГЕН РАН)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Федеральное государственное бюджетное учреждение науки Институт общей генетики им. Н.И. Вавилова Российской академии наук (ИОГЕН РАН) filed Critical Федеральное государственное бюджетное учреждение науки Институт общей генетики им. Н.И. Вавилова Российской академии наук (ИОГЕН РАН)
Priority to RU2015111612A priority Critical patent/RU2614234C2/en
Publication of RU2015111612A publication Critical patent/RU2015111612A/en
Application granted granted Critical
Publication of RU2614234C2 publication Critical patent/RU2614234C2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Фармацевтическая композиция для терапии злокачественных опухолей, содержащая, как минимум один активный компонент - фармацевтически приемлемый 3-(3,5-Диметилпиразол-1-ил)имидазо[1,2-b][1,2,4,5]тетразин формулы (I), и как минимум два вспомогательных вещества- ацетонитрил и D-маннит.A pharmaceutical composition for the treatment of malignant tumors containing at least one active component, a pharmaceutically acceptable 3- (3,5-dimethylpyrazol-1-yl) imidazo [1,2-b] [1,2,4,5] tetrazine of the formula ( I), and at least two excipients - acetonitrile and D-mannitol.

Claims (1)

Фармацевтическая композиция для терапии злокачественных опухолей, содержащая, как минимум один активный компонент - фармацевтически приемлемый 3-(3,5-Диметилпиразол-1-ил)имидазо[1,2-b][1,2,4,5]тетразин формулы (I), и как минимум два вспомогательных вещества- ацетонитрил и D-маннит. A pharmaceutical composition for the treatment of malignant tumors containing at least one active component, a pharmaceutically acceptable 3- (3,5-dimethylpyrazol-1-yl) imidazo [1,2-b] [1,2,4,5] tetrazine of the formula ( I), and at least two excipients - acetonitrile and D-mannitol.
RU2015111612A 2015-03-31 2015-03-31 PHARMACEUTICAL COMPOSITION BASED ON 3-(4-METHYLIMIDAZOLE-1-YL)IMIDAZO[1,2-b][1,2,4,5]TETRAZINE AS ANTI-TUMOR AGENT RU2614234C2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
RU2015111612A RU2614234C2 (en) 2015-03-31 2015-03-31 PHARMACEUTICAL COMPOSITION BASED ON 3-(4-METHYLIMIDAZOLE-1-YL)IMIDAZO[1,2-b][1,2,4,5]TETRAZINE AS ANTI-TUMOR AGENT

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2015111612A RU2614234C2 (en) 2015-03-31 2015-03-31 PHARMACEUTICAL COMPOSITION BASED ON 3-(4-METHYLIMIDAZOLE-1-YL)IMIDAZO[1,2-b][1,2,4,5]TETRAZINE AS ANTI-TUMOR AGENT

Publications (2)

Publication Number Publication Date
RU2015111612A true RU2015111612A (en) 2016-10-20
RU2614234C2 RU2614234C2 (en) 2017-03-23

Family

ID=57138264

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2015111612A RU2614234C2 (en) 2015-03-31 2015-03-31 PHARMACEUTICAL COMPOSITION BASED ON 3-(4-METHYLIMIDAZOLE-1-YL)IMIDAZO[1,2-b][1,2,4,5]TETRAZINE AS ANTI-TUMOR AGENT

Country Status (1)

Country Link
RU (1) RU2614234C2 (en)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10157628A1 (en) * 2001-11-26 2003-06-12 Zentaris Ag Solution for injection of an LHRH antagonist
RU2462466C1 (en) * 2011-06-24 2012-09-27 Автономная Некоммерческая Организация "Научно-Исследовательский Центр Биотехнологии Антибиотиков И Других Биологически Активных Веществ "Биоан" Substituted azolo[1,2,4,5]tetrazines - inhibitors of antibacterial serine-threonine protein kinases
RU2527258C1 (en) * 2013-02-19 2014-08-27 Автономная Некоммерческая Организация "Научно-Исследовательский Центр Биотехнологии Антибиотиков И Других Биологически Активных Веществ "Биоан" 6-SUBSTITUTED 3-AZOLYLIMIDAZO[1,2-b][1,2,4,5]TETRAZINES SHOWING ANTICANCER ACTIVITY

Also Published As

Publication number Publication date
RU2614234C2 (en) 2017-03-23

Similar Documents

Publication Publication Date Title
PH12020551315A1 (en) Benzoxazepin oxazolidinone compounds and methods of use
CA2999253C (en) Heterocyclic compounds and uses thereof
PH12018500284A1 (en) 5-bromo-2,6-di-(1h-pyrazol-1-yl)pyrimidin-4-amine for use in the treatment of cancer
WO2015070224A3 (en) Combination therapy including an mdm2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
EA201990846A1 (en) BENZO [b] THIOPHENE COMPOUNDS AS STING AGONISTS
SA518392101B1 (en) Benzimidazole Derivatives as Modulators of ROR-GAMMA
BR112017003054A2 (en) aminopyrimidinyl compounds as jak inhibitors
NZ752526A (en) Pyrrolobenzodiazepine conjugates
PH12016500024A1 (en) Bromodomain inhibitor
MY196909A (en) Boronic acid derivatives and therapeutic uses thereof
PH12018501920A1 (en) Bromodomain inhibitors
MX2020001403A (en) Quinoline derivatives for treating infections with helminths.
PH12016501355A1 (en) Bicyclic heterocyclic derivatives as bromodomain inhibitors
GEP20237470B (en) Magl inhibitors
WO2014188178A9 (en) Polymyxin derivatives and their use in combination therapy together with different antibiotics
GEP20227443B (en) Magl inhibitors
EA201692542A1 (en) INDANEOUS AND INDOLINE DERIVATIVES AND THEIR APPLICATION AS ACTIVATORS OF SOLUBLE GUANYLATSYCLASES
MX2022002976A (en) Jak1 selective inhibitors.
EA201500942A1 (en) ANTI-VIRUS INDOLO [2,3-b] HINOXALINE
EA202091169A1 (en) SMAC MIMETICS USED AS IAP INHIBITORS AND THEIR APPLICATION
EA201891680A1 (en) INDAN DERIVATIVES AS MGLUR7 MODULATORS
RU2015111612A (en) Pharmaceutical composition based on 3- (3,5-Dimethylpyrazol-1-yl) imidazo [1,2-b] [1,2,4,5] tetrazine as an antitumor agent
RU2012148768A (en) PHARMACEUTICAL COMPOSITION BASED ON THE TRIINDOLYLMETHANE DERIVATIVE AS AN ANTUMOR AGENT
MX369874B (en) Pharmaceutical composition for the treatment of erectile dysfunction, based on a drug, in a gel, inhibiting the pde5 enzyme (phosphodiesterase type 5).

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20200401